Palatin Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Palatin Technologies, Inc.
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
Among Vaxxinity’s immunotherapeutic vaccine candidates are one for Alzheimer’s that shows a 50% reduction in cognitive decline, another that shows superior durability than Pfizer and Moderna’s COVID-19 vaccines and one that could prevent migraines. Vaxxinity CEO speaks to Scrip about these and more in this interview
NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.
Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.
- Large Molecule